Introduction
The impact of psychosocial factors, including depressive symptoms, on the outcomes of dialysis patients has been emphasized in several studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In the Dialysis Outcomes and Practice Patterns Study (DOPPS), the presence of depressive symptoms, as assessed by the Center for Epidemiologic Studies Depression Scale (CES-D) or by the two depression questions on the Medical Outcomes Study Short Form-36 (SF-36), was strongly associated with mortality and hospitalizations in a large cohort of prevalent hemodialysis (HD) patients maintained on dialysis for a median time of >2.4 years [4] .
High mortality rates during the first year of end-stage renal disease (ESRD) for patients maintained on HD has captured the renal community's attention [16] . While 25-30% of prevalent ESRD patients have clinical depression [8] , Watnick et al. [17] observed that among 123 incident dialysis patients screened within 10 days of starting dialysis, 44% had Beck Depression Inventory (BDI) scores above the validated cutoff for clinical depression. Two recent studies have begun to focus their attention on the association of depressive symptoms and mortality in chronic kidney disease and incident ESRD patients [13, 14] . Although with small sample sizes, their findings suggest that depressive symptoms in the period prior to dialysis and shortly after initiation of dialysis are associated with higher mortality risk.
The present study was designed to evaluate a potential relationship between depressive symptoms (based on response to the two questions from the SF-36) reported within the first 90 days after the start of HD and both mortality and separately, withdrawal from dialysis, in a large cohort of incident HD patients at the end of the first year after starting dialysis therapy. If so, the question of possible therapeutic implications of evaluating for clinical depression and managing patients with depressive symptoms on outcomes of incident dialysis patients would need to be considered.
Materials and methods

Study population and follow-up
The study cohort consisted of 6415 HD patients admitted to Fresenius Medical Care North America (FMCNA) facilities between 1 January 2006 to 31 December 2006 who completed the SF-36 surveys with calculated physical and mental component scores (PCS/MCS) [18] . Patients were followed for up to 1 year from the date of SF-36 survey. Deaths and withdrawal from dialysis (based on a physiciandocumented informed decision by the patient and/or guardian to stop dialysis treatments, most often leading to death) were each tracked separately as co-primary outcomes. Patients who recovered kidney function, received a kidney transplant or left the FMCNA system all contributed person-time at risk but were censored upon occurrence of these events.
SF-36 questions associated with depressive symptoms
There are five mental health (MH) domain items in SF-36 [18] designed to determine the frequency of: (i) being nervous, (ii) being down in the dumps, (iii) feeling calm and peaceful, (iv) feeling downhearted and blue and (v) being happy. Consistent with the literature, we utilized 2 of the 5 items in the MH section of the SF-36 questionnaire as indicators for a presumptive diagnosis of depression:
MH#2: Have you felt so down in the dumps nothing could cheer you up? (i.e. 'dumps').
MH#4: Have you felt downhearted and blue? (i.e. 'Blue').
Both items used a 6-point choice of responses: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time or 6 = none of the time.
Statistical methods
In Phase 1, self-reported responses of 1-3 (i.e. frequency at or more than: 'a good bit of the time') for SF-36 questions MH#2 and MH#4 were used to indicate potentially significant depressive symptoms [4, 19] . Cox's proportional hazards regression models for both outcomes (death and withdrawal from dialysis) were performed separately, both as unadjusted models and adjusted for case-mix (age, gender, race and presence of a diagnosis of diabetes) and for case-mix plus laboratory results (mean of all available results prior to date of survey for albumin, hemoglobin, transferrin saturation, phosphorus, calcium and creatinine). Finally, MCS and PCS were each added to the case-mix plus laboratory adjusted models to verify that the 'depressive symptoms variable' provided incremental prognostic information beyond the SF-36 summary scores with potential collinearity evaluated using the variance inflation factor (VIF). In Phase 2, due to the overlap between MCS and the categorical variable for depressive symptoms, we utilized a continuous variable to represent depressive symptoms to facilitate disaggregating and quantifying the contribution of the 'dumps' and 'blue' questions from both the MH domain score and the MCS. Item scores were 'reversed' so that the higher value represents having more frequent depressive symptoms:
Then, the revised 'depression score' was defined as:
From the equation, depression score represents the mean of reversed (i.e. higher score is worse) MH2 and MH4 responses, recorded as a continuous variable ranging from 1 to 6. To facilitate the presentation of descriptive comparisons of case-mix variables and laboratory values, we arbitrarily categorized patients into three groups by mean depression score: unlikely depressed (≤2), possibly depressed (>2 to< 5) and likely depressed (≥5 to 6). Analysis of variance was applied to continuous variables and chi-square tests for categorical variables. Pearson correlation coefficients between the depression scores and continuous variables were also determined. The Kaplan-Meier estimates of survival rates were also calculated monthly for 1 year comparing the three groups to gauge face validity of the converted depression score as a mortality predictor.
The MH domain contribution was carved out of the MCS and then further subdivided into the five component questions. To begin, scores for all MCS variables were standardized and then the MH domain items were subtracted from the MCS. A factor analysis with varimax rotation was then performed, which supported disaggregating the two depression questions from the three remaining questions in the MH domain (results are shown in the Supplementary Appendix). The MH domain clustered into three areas: depression score (mean of dumps and blue), being nervous (MH#1) and mean of not being 'calm/peaceful/happy' (MH#3 and MH#5).
Cox's proportional hazards regression models for both death and withdrawal from dialysis were constructed. However, instead of simply adding fixed covariates representing case-mix and laboratory variables a priori as done in Phase 1, we elected to adjust using stepwise variable selection in order to optimize the models. Three models were constructed in the following sequence: (i) Model 1, unadjusted univariable models for each of the determinant variables: depression score (as a continuous variable), being nervous, not calm/peaceful/happy, age, PCS, MCS, other demographic and clinical variables that now include insurance status on the date of survey and laboratory data were individually constructed, (ii) Model 2, a stepwise regression model was utilized to select the best risk model from a quality of life perspective that a priori, forced the entry of age, then included the following variables as candidates for the stepwise procedure (alpha threshold = 0.05 for both inclusion and removal): the MH items (separated into depression score, not calm/ peaceful/happy and nervous; consistent with the results from the factor analysis), a modified MCS that carved out the MH domain, PCS and insurance status on the date of survey and (iii) Model 3, adding case-mix covariate options to Model 2, such as: gender, race, diabetes, plus laboratory values, to include albumin, calcium, creatinine, hemoglobin, phosphorus and transferrin saturation. Proportionality assumptions were assessed.
Post-hoc, a sensitivity analysis was performed, whereby we included a variable representing the vintage on the date of survey (in days) in all the adjusted models to determine if it was a potential confounder. All statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).
Results
The study cohort (N = 6415 patients) had a mean age of 62.3 ± 15.2 years, with 45% female, 69% Caucasian and 58% with a diagnosis of diabetes, shown in Table 1 . The mean scores for PCS and MCS at baseline were 31.9 ± 10.0 and 46.5 ± 11.5, respectively. There were 784 deaths (12.2%) and 285 (4.4%) withdrawals during the yearlong follow-up period following the date of survey. Overall, there were 784 deaths (12.2%), 284 withdrawals (4.4%), 216 renal transplants (3.4%) and 501 patients who transferred out of the system and/or were lost to follow-up (7.8%).
Phase 1 (frequent depressive symptoms as a categorical variable)
Frequent depressive symptoms based on SF-36 (at or more than a good bit of the time) were reported in 14.1% of patients for the question we refer to as dumps, 16 .1% for the other question we refer to as blue and 20.8% for either question i.e. 'dumps or blue' (without double counting overlap). Patients reporting frequent depressive symptoms also reported slightly lower PCS and much lower MCS. They were younger but had lower serum albumin and creatinine ( Table 1 ). The combined dumps or blue category exhibited unadjusted mortality hazard ratio (HR) = 1.24 (1.28, 1.43), case-mix adjusted HR = 1.36 (1.19, 1.57) and case-mix plus laboratory adjusted HR = 1.32 (1.05, 1.79) shown in Figure 1A . The corresponding HR for withdrawal from dialysis was 1.37 (1.05, 1.79), 1.56 (1.20, 2.04) and 1.62 (1.24, 2.13), respectively ( Figure 1B) . However, when we included MCS into any of the models, the depressive symptoms variable lost statistical significance. The correlation between MCS and dumps was − 0.48 and for blue was − 0.50 (both P < 0.0001), although they each had collinearity evaluated, with both VIF test results of< 1 indicating low collinearity.
Phase 2 (depressive symptoms as a continuous depression score variable)
Consistent with Phase 1 results, a higher depression score was associated with overall lower MCS (r = − 0.73) likely because the latter was derived from two of the five questions that form part of the MH domain component of the MCS. This correlation was reduced to − 0.08 with the modified MCS that excluded contribution from the MH domain. Depression scores weakly correlated with younger age and lower PCS, albumin and creatinine. Based on depression scores: unlikely depressed (≤2), possibly depressed (>2 to< 5) and likely depressed (≥5-6), there was a decline in PCS: 32.7, 30.9 and 30.6 and in MCS, 52.5, 39.2 and 28.2, respectively (both P< 0.0001), shown in Table 2 . Mean age declined with worsening depression scores at 63.0, 61.5 and 59.6 years, respectively (P < 0.0001). This was consistent even in the subset of patients< 50 years and in those >70 years of age. There was a mild upward trend for proportion of women with worsening depression scores (44, 47, versus 48%, P = 0.05), while race and diabetes were not significantly different between groups. Consistent with their weak correlation with depression scores, two laboratory measurements, albumin and creatinine, were significantly different across the three groups, albeit by relatively narrow gradation: 3.53, 3.50 and 3.45 g/dL (P = 0.0003) and 6.2, 6.0 and 5.9 mg/dL, respectively (P < 0.0001).
The cumulative death rates during the year for each category of depression scores were 12.0, 14.5 and 16.3, respectively. Corresponding cumulative withdrawal rates were 4.3, 5.8 and 7.3%, respectively. There were significant differences among three survival curves for unlikely depressed, possibly depressed and likely depressed patient groups for both death ( Figure 2A ) and withdrawal ( Figure 2B ) from dialysis (both P = 0.006).
From Table 3 , Model 1 (i.e. univariable analyses), depression score yielded HR = 1.09 (1.03-1.15). Recall that this continuous depression variable was scaled from 1 to 6 and when reversed the higher score reflected worsening depression. Thus, a 1-unit increment in depression score would yield an increase of 9% in the relative risk of death. The combined variable representing 'not calm/ peaceful/happy' was significantly associated with mortality (P < 0.001), while 'nervous' and modified MCS (without MH components) were not. In Model 2, where age was entered as an independent variable along with a stepwise selection process for SF-36 derived variables (e. g. MH factors, MCS modified to exclude the MH domain, PCS) and insurance status, depression score remained significantly associated with mortality risk with minimal change in HR at 1.09 (1.03-1.16), while the other two MH items (nervous and not calm/peaceful/ happy) were deleted by the stepwise procedure. Age, PCS and modified MCS also remained significant. Thus, there a All P-values were based on comparison to the 'neither dumps/blue' group. *P < 0.05; **P < 0.01; ***P < 0.0001.
was minimal overlap between the impact of modified MCS and depression score. In Model 3, which was similar to Model 2 but with eligibility for stepwise selection of case-mix and laboratory variables, there was minimal attenuation of the incremental mortality risk associated with depression score at HR = 1.08 (101, 1.14). Age, PCS and modified MCS remained significantly associated with mortality as well, shown in Table 3 .
Results for association with dialysis withdrawal are shown in Table 4 . Depression score associated with dialysis withdrawal at HR = 1.15 (1.05, 1.26) but was dropped from the first stepwise model (Model 2) when age and the other quality of life component scores were included. However, in Model 3, depression score again reappeared as a significant associate of withdrawal, with HR = 1.19 (1.08-1.31), despite stepwise addition of all other significant quality of life, case-mix and laboratory variables in the model. The nervous and not calm/peaceful/happy components of MH were significant predictors of withdrawal in Model 2 but were no longer significant in Model 3, indicating some competing assignment of risk between these MH components and the depression scores. Sensitivity analyses that incorporated vintage on the date of survey did not change any of the death and withdrawal model results (data not shown).
Discussion
The present study examined the association between depressive symptoms assessed predominantly between 10 and 90 days after initiating HD (mean ± SD: 46 ± 24 days, median: 49 days) and outcomes in the first year. Our findings suggest that the presence of depressive symptoms is associated with a significant increase in 1-year mortality of 32% after correction for clinical and laboratory features using previously validated methodology. The potential impact may be greater with increased severity of depressive symptoms as quantified by our depression score, derived from the SF-36 questionnaire. These findings Fig. 1 . Cox models illustrating the association between frequent depressive symptoms assessed from the two SF-36 questions ('dumps'/'blue') and (A) mortality and (B) withdrawal from dialysis therapy. support the observations of Chilcot et al. [14] who evaluated the relationship between depressive symptoms (assessed by the BDI-11 questionnaire) and mortality risk in a small cohort of incident HD patients followed for a mean of 511 days.
The two questions indicative of depressive symptoms on the SF-36 were used as the assessment tool in this study. Similarly, DOPPS investigators used these same two questions and demonstrated an association between scores on these two questions and mortality and hospitalization rates in a large cohort of prevalent ESRD patients who had been maintained on HD for a median of 2.5 years [4] . They went on to examine depressive symptoms using the CES-D questionnaire and confirmed their findings from the two SF-36 questions. The utility of brief screening questions for the evaluation of depression is well documented. For example, two questions from the Patient Health Questionnaire (PHQ)-2 have a high sensitivity and specificity for predicting depression scores assessed with the full 9-question version (PHQ-9) in the general medical population [20, 21] . And, in Areas shaded dark gray represent variables that were not included in the pool of covariates for Model 2, while light gray areas represent available covariates that were excluded by the stepwise procedure. Model 1-simple (univariable) regression. Model 2-stepwise regression with depression level, age, PCS, MCS without MH and MH components. Model 3-stepwise regression as in Model 2 with addition of all other case-mix and laboratory variables. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Areas shaded dark gray represent variables that were not included in the pool of covariates for Model 2, while light gray areas represent available covariates that were excluded by the stepwise procedure. Model 1: simple regression; one at a time. Model 2: stepwise regression with depression level, age, PCS, MCS without MH and MH components. Model 3: stepwise regression as in Model 2 with addition of all case-mix and laboratory variables. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
ESRD patients, the two depression questions from the SF-36 are strongly correlated with BDI scores [19] . One of the challenges in interpreting the relationship between depressive symptoms and mortality relates to the association of depression scores with other MH scores on standardized questionnaires. For example, in the present study, a strong association was observed between the scores on the depression questions and the MCS score on the SF-36 (Table 2 ). This is not surprising since the depression questions are key components of the MCS score. However, since the MCS score has been shown to be a strong predictor of mortality and hospitalization rates in prevalent HD patients, we thought it important to sort out the relative contribution of the depression scores from the other components of the MH and MCS scores as contributors to the mortality risk (i.e. recall that the two 'depression' questions represent two of the five contributors to the MH score, while the MH domain is one of the four domains contributing to the MCS score).
Although the DOPPS study also evaluated the two questions separately as continuous variables relative to outcome [4] , the current study is the first to disaggregate the prognostic contribution of the two SF-36 questions from the MH and MCS. To accomplish this, we examined the separate components of the MH score and then removed the five questions that contribute to the MH portion of the MCS score. This analysis (Table 3) confirms that the depression score is strongly associated with 1-year mortality using stepwise regression with adjustment for case-mix and laboratory variables. The findings also underscore the importance of other psychosocial factors on outcomes since when the components of the MH score were removed from the MCS score, a significant association between the resultant score and mortality persisted. In addition, a strong relationship between PCS scores and mortality was observed, confirming previous observations in cross-sectional studies of prevalent HD patients [22] [23] [24] .
The reasons why depressive symptoms are associated with mortality are complex and have recently been reviewed [25] . Possible explanations include reduced compliance with medical treatment regimens, exacerbation of cardiovascular disease and withdrawal from dialysis. The present study suggests that withdrawal from dialysis as a cause of death is increased dramatically in patients with depressive symptoms (Table 4) . We note that more frequent depressive symptoms in this study were more prevalent with younger age and associated with lower albumin and creatinine levels-perhaps indicative of a greater burden of illness represented by malnutrition/ inflammation and/or decreased muscle mass. However, we were also intrigued by the prospect of a potentially greater impact of managing depressive symptoms in this younger age group.
Much attention has recently been focused on the high mortality for incident HD patients in the initial year of therapy [26, 27] . Strategies are now being developed to try to reduce this mortality rate [16] . Reductions in catheter utilization, patient education, coordinated dialysis facility care and early nephrology referral are all being encouraged to improve patient outcomes in the initial period of dialysis. The present study raises the question of whether addressing depressive symptoms could result in improved outcomes. Initially, the presence of clinical depression would need to be confirmed with direct patient interviews; then, if clinical depression was present, various treatment options would need to be considered. Several studies have now shown that various treatments, including antidepressant medications [25] , cognitive behavioral therapy [28] , changes in the dialysis treatment regimen (e.g. to more frequent dialysis) [29] , exercise programs [30] and active case management can result in a reduction in depressive symptoms in ESRD patients. What remains unanswered, however, is whether institution of these treatments with resultant reduction in depressive symptomatology translates into improvements in mortality and/or hospitalization rates. This critically important question needs to be addressed in future studies.
Although the present study's strengths include a large sample size and a national source population, it has several limitations. First, the study is a retrospective analysis of observational data. Therefore, our associations herein do not necessarily prove causation. Next, depressive symptoms were assessed with only the two questions from the SF-36 rather than with a full depression questionnaire or direct patient interview. However, results from prior studies indicate that 'depressive' responses to these two questions have been shown to correlate very well with the diagnosis of depression. Third, there are multiple unadjusted factors such as marital status/social support, income level, education and other factors that likely contributed to residual confounding.
In conclusion, the early period immediately after initiating dialysis has been identified as one of the highest risk for death and hospitalization. Our findings support the notion that depressive symptoms may contribute, at least in part, to the burden of illness in these incident HD patients. We posit that prospective intervention trials are needed in this population to determine whether or not ascertainment of depression status and subsequent therapy during this vulnerable period may improve symptoms, enhance survival and/or decrease premature withdrawal from dialysis.
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